For the year ending 2025-12-31, APRE made $285,759 in revenue. -$12,606,904 in net income. Net profit margin of -4411.73%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Grant revenue | 285,759 | 1,502,581 | ||
| Research and development | 7,043,035 | 9,363,537 | ||
| General and administrative | 6,476,560 | 6,458,699 | ||
| Total operating expenses | 13,519,595 | 15,822,236 | ||
| Loss from operations | -13,233,836 | -14,319,655 | ||
| Interest income, net | 652,086 | 1,289,144 | ||
| Other income | 77,500 | - | ||
| Foreign currency (loss) gain | -95,319 | 71,800 | ||
| Total other income | 634,267 | 1,360,944 | ||
| Net loss | -12,599,569 | -12,958,711 | ||
| Foreign currency translation | -7,335 | -16,106 | ||
| Total comprehensive loss | -12,606,904 | -12,974,817 | ||
| Basic EPS | -1.93 | -2.35 | ||
| Diluted EPS | -1.93 | -2.45 | ||
| Basic Average Shares | 6,538,722 | 5,509,921 | ||
| Diluted Average Shares | 6,538,722 | 5,509,921 | ||
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)